Peroxisome proliferator-activated receptor agonists and bladder cancer: Lessons from animal studies

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 30, Issue 4, 2012, Pages 368-402

  Tseng, Chin Hsiao ^a   Tseng, Farn Hsuan ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

animal study; antidiabetic drugs; bladder cancer; mode of action; Peroxisome proliferator activated receptor agonists; pioglitazone; thiazolidinedione

Indexed keywords

ANIMAL STUDIES; ANTIDIABETIC DRUG; BLADDER CANCERS; MODE OF ACTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PIOGLITAZONE; THIAZOLIDINEDIONES;

ANIMALS; BIOMINERALIZATION; CYTOLOGY; PATHOLOGY; RATS;

DISEASES;

CITRIC ACID; EPIDERMAL GROWTH FACTOR; FENOFIBRATE; GEMFIBROZIL; MURAGLITAZAR; NAVEGLITAZAR; OXALIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; TROGLITAZONE;

ANGIOSARCOMA; BLADDER CANCER; CANCER RISK; DOSE RESPONSE; DRUG CARCINOGENICITY; DRUG CYTOTOXICITY; DRUG MEGADOSE; ETHNIC DIFFERENCE; GENOTOXICITY; HYPERTROPHY; HYPOCALCIURIA; LATENT PERIOD; LIVER CELL CARCINOMA; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; SPECIES DIFFERENCE; TRANSITIONAL CELL CARCINOMA; URINE ACIDIFICATION; UROLITHIASIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RATS; SEX FACTORS; SPECIES SPECIFICITY; URINARY BLADDER NEOPLASMS; UROLITHIASIS;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 84870549306     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590501.2012.735519     Document Type: Review

References (99)

1. Krishnaswami A, Ravi-Kumar S, Lewis JM. Thiazolidinediones: a 2010 perspective. Perm J. 2010;14:64-72.
2. El-Hage J. Peroxisome proliferation-activated receptor agonists: carcinogenicity findings and regulatory recommendations. In International Atherosclerosis Society Symposiumon PPAR, Monte Carlo, 2005.
3. Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H, Cohen SM. Effectsof pioglitazone, a peroxisome proliferator-activated receptor gamma agonist,on the urine and urotheliumof the rat. Toxicol Sci. 2010;113:349-357.
4. Berger J, Moller DE. The mechanismsof actionof PPARs. Annu Rev Med. 2002;53:409-435.
5. Tachibana K, Yamasaki D, Ishimoto K, Doi T. The roleof PPARs in cancer. PPAR Res. 2008;2008:102737.
6. Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med. 2005;353:604-615. (Pubitemid 41138942)
7. Aoki T. Current statusof carcinogenicity assessmentof peroxisome proliferatoractivated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential. J Toxicol Pathol. 2007;20:197-202.
8. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
9. Waites CR, Dominick MA, Sanderson TP, Schilling BE. Nonclinical safety evaluationof muraglitazar, a novel PPARalpha/gamma agonist. Toxicol Sci. 2007;100:248-258. (Pubitemid 47617821)
10. Hellmold H, Zhang H, Andersson U, Blomgren B, Holland T, Berg AL, et al. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol Sci. 2007;98:63-74. (Pubitemid 47073822)
11. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary preventionof macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279- 1289. (Pubitemid 41416583)
12. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Riskof bladder cancer among diabetic patients treated with pioglitazone: interim reportof a longitudinal cohort study. Diabetes Care. 2011;34:916-922.
13. Neumann A,Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and riskof bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953-1962.
14. Tseng CH. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analysesor different ethnicities? J Formos Med Assoc. 2012;111:123-131.
15. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2008;2:47-57. (Pubitemid 351194192)
16. Tseng CH. Diabetes and riskof bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011;54:2009-2015.
17. Tseng CH. Pioglitazone and bladder cancer: a population-based studyof Taiwanese. Diabetes Care. 2012;35:278-280.
18. Cohen SM. Effectsof PPARgamma and combined agonistson the urinary tractof rats andother species. Toxicol Sci. 2005;87:322-327. (Pubitemid 41300679)
19. Oleksiewicz MB, Southgate J, Iversen L, Egerod FL. Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma agonists. PPAR Res. 2008;2008:103167.
20. Oleksiewicz MB, Thorup I, Nielsen HS, Andersen HV, Hegelund AC, Iversen L, et al. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol Pathol. 2005;33:552-560. (Pubitemid 41473090)
21. Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB. Biomarkers for early effectsof carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers. 2005;10:295-309. (Pubitemid 41448390)
22. DominickMA, WhiteMR, Sanderson TP, Van Vleet T, Cohen SM, Arnold LE, et al. Urothelial carcinogenesis in the urinary bladderofmale rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the modeof action. Toxicol Pathol. 2006;34:903-920. (Pubitemid 46011143)
23. Achanzar WE, Moyer CF, Marthaler LT, Gullo R, Chen SJ, French MH, et al. Urine acidification has no effecton peroxisome proliferator-activated receptor (PPAR) signalingor epidermal growth factor (EGF) expression in rat urinary bladder urothelium. Toxicol Appl Pharmacol. 2007;223:246-256. (Pubitemid 47362223)
24. Tannehill-Gregg SH, Sanderson TP, Minnema D, Voelker R, Ulland B, Cohen SM, et al. Rodent carcinogenicity profileof the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci. 2007;98:258-270. (Pubitemid 47073837)
25. Van Vleet TR, White MR, Sanderson TP, Cohen SM, Cano M, Arnold LL, et al. Subchronic urinary bladder effectsof muraglitazar in male rats. Toxicol Sci. 2007;96:58-71. (Pubitemid 46323209)
26. Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladderof rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lackof evidence for urolithiasis as an inciting event. Toxicol Pathol. 2008;36:218-231. (Pubitemid 351545780)
27. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: potent promoterof hydroxybutyl(butyl) nitrosamineinduced urinary bladder cancers. Int J Cancer. 2008;123:2254-2259.
28. Sato K, Awasaki Y, Kandori H, Tanakamaru ZY, Nagai H, Baron D, Yamamoto M. Suppressive effectsof acid-forming diet against the tumorigenic potentialof pioglitazone hydrochloride in the urinary bladderof male rats. Toxicol Appl Pharmacol. 2011;251:234-244.
29. Simutis FJ, Sanderson TP, Dominick MA, Schilling BE, Waites CR, Minnema D, Voelker R, Ulland B. Carcinogenicity studiesof muraglitazar, a dual PPAR alpha and gamma agonist, in mice and rats. Toxicol Sci. 2006(Suppl.):429.
30. El-Hage J. Toxicity profilesof peroxisome proliferator-activated receptor (PPAR) agonists and preclinical safety profile for muraglitazar. 2005. www.fda.gov/ohrms/ dockets/ac/05/slides/2005-4169S2 02 02-FDA-ElHage. pt
31. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, et al. PPARalpha agonist-induced rodent tumors: modesof action and human relevance. Crit Rev Toxicol. 2003;33:655-780. (Pubitemid 38037444)
32. Lai DY. Rodent carcinogenicityof peroxisome proliferators and issueson human relevance. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2004;22:37- 55. (Pubitemid 38802823)
33. Nesfield SR, Clarke CJ, Hoivik DJ, Miller RT, Allen JS, Selinger K, Santostefano MJ. Evaluationof the carcinogenic potentialof clofibrate in the rasH2 mouse. Int J Toxicol. 2005;24:301-311.
34. Takeda Pharmaceuticals America, Inc. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. 2009. http://www.actos.com/actospro/home. aspx (accessed May 16, 2011)
35. US Food and Drug Administration. FDA drug safety communication:ongoing safety reviewof actos (pioglitazone) and potential increased riskof bladder cancer after two years exposure. http://www.fda.gov/Drugs/DrugSafety/ucm226214. tm (accessed February 7, 2012)
36. US package insert, 2008.http://www.accessdata.fda.gov/drugsatfda docs/label/ 2008/021073s034lbl.pdf (accessed August 12, 2011)
37. US Food and Drug Administration. The drug approval package for Actos (pioglitazone hydrochloride) tablets. Application No. 021073.1999 http://www. accessdata.fda.gov/drugsatfda docs/nda/99/021073A Actos.cfm (accessed August 12, 2011)
38. Herman JR, Dethloff LA, McGuire EJ, Parker RF, Walsh KM, Gough AW, Masuda H, de la Iglesia FA. Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol Sci. 2002;68:226-236. (Pubitemid 34785244)
39. Long GG, Reynolds VL, Dochterman LW, Ryan TE. Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/ gamma agonist. Toxicol Pathol. 2009;37:741-753.
40. Nahlé Z. PPAR trilogy from metabolism to cancer. Curr Opin Clin Nutr Metab Care. 2004;7:397-402. (Pubitemid 40340645)
41. Guan Y, Zhang Y, Davis L, Breyer MD. Expressionof peroxisome proliferatoractivated receptors in urinary tractof rabbits and humans. Am J Physiol. 1997;273:F1013-1022.
42. Gardner OS, Dewar BJ, Earp HS, Samet JM, Graves LM. Dependenceof peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signalingon epidermal growth factor receptor transactivation. J Biol Chem. 2003;278:46261-46269. (Pubitemid 37452196)
43. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H. Differential regulationof vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem. 2002;277:23534-23543. (Pubitemid 34952189)
44. Ledwith BJ, Manam S, Troilo P, Joslyn DJ, Galloway SM, Nichols WW. Activationof immediate-early gene expression by peroxisome proliferators in vitro. Mol Carcinog. 1993;8:20-27. (Pubitemid 23253576)
45. Egerod FL, Svendsen JE, Hinley J, Southgate J, Bartels A, Brunner N, Oleksiewicz MB. PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nucleiof the dorsal and ventral urinary bladder and kidney pelvis urotheliumof rats. Toxicol Pathol. 2009;37:947-958.
46. Egerod FL, Brunner N, Svendsen JE, Oleksiewicz MB. PPARalpha and PPARgamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. J Appl Toxicol. 2010;30:151-162.
47. Cohen SM, Garland EM, Cano M, St John MK, Khachab M, Wehner JM, Arnold LL. Effectsof sodium ascorbate, sodium saccharin and ammonium chlorideon the male rat urinary bladder. Carcinogenesis. 1995;16:2743-2750.
48. Cohen SM. Cell proliferation in the bladder and implications for cancer risk assessment. Toxicology. 1995;102:149-159.
49. Burin GJ, Gibb HJ, Hill RN. Human bladder cancer: evidence for a potential irritation-induced mechanism. Food Chem Toxicol. 1995;33:785-795.
50. Cohen SM. Roleof urinary physiology and chemistry in bladder carcinogenesis. Food Chem Toxicol. 1995;33:715-730.
51. Hard GC. Species comparisonof the content and compositionof urinary proteins. Food Chem Toxicol. 1995;33:731-746.
52. Lina BA, Kuijpers MH. Toxicity and carcinogenicityof acidogenicor alkalogenic diets in rats; effectsof feeding NH(4)Cl, KHCO(3)or KCl. Food Chem Toxicol. 2004;42:135-153. (Pubitemid 37421333)
53. Poore RE, Hurst CH, Assimos DG, Holmes RP. Pathwaysof hepaticoxalate synthesis and their regulation. Am J Physiol. 1997;272:C289-294.
54. Genolet R, Kersten S, Braissant O, Mandard S, Tan NS, Bucher P, Desvergne B, Michalik L, Wahli W. Promoter rearrangements cause species-specific hepatic regulationof the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor alpha. J Biol Chem. 2005;280:24143- 24152. (Pubitemid 40884902)
55. Cohen SM, Ohnishi T, Clark NM, He J, Arnold LL. Investigationsof rodent urinary bladder carcinogens: collection, processing, and evaluationof urine and bladders. Toxicol Pathol. 2007;35:337-347. (Pubitemid 46450081)
56. Hardisty JF, Anderson DC, Brodie S, Cline JM, Hahn FF, Kolenda-Roberts H, et al. Histopathologyof the urinary bladdersof cynomolgus monkeys treated with PPAR agonists. Toxicol Pathol. 2008;36:769-776.
57. Reese DH, Friedman RD. Suppressionof dysplasia and hyperplasia by calcium inorgan-cultured urinary bladder epithelium. Cancer Res. 1978;38:586-592. (Pubitemid 8311399)
58. Benigni R, Bossa C, Giuliani A, Tcheremenskaia O. Exploring in vitro/in vivo correlation: lessons learned from analyzing phase I resultsof the US EPA's Tox- Cast Project. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010;28:272- 286.
59. Varley CL, Stahlschmidt J, Lee WC, Holder J, Diggle C, Selby PJ, et al. Roleof PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci. 2004;117:2029-2036. (Pubitemid 38745136)
60. Momose H, Kakinuma H, Shariff SY,Mitchell GB, Rademaker A, Oyasu R. Tumorpromoting effectof urinary epidermal growth factor in rat urinary bladder carcinogenesis. Cancer Res. 1991;51:5487-5490.
61. Oyasu R. Epithelial tumoursof the lower urinary tract in humans and rodents. Food Chem Toxicol. 1995;33:747-755.
62. Cohen SM, Lawson TA. Rodent bladder tumors do not always predict for humans. Cancer Lett. 1995;93:9-16.
63. Elcock M, Morgan RW. Updateon artificial sweeteners and bladder cancer. Regul Toxicol Pharmacol. 1993;17:35-43.
64. Zhang Y, Zhu C, Curado MP, Zheng T, Boyle P. Changing patternsof bladder cancer in the USA: evidenceof heterogeneous disease. BJU Int. 2012;109:52-56.
65. DeSesso JM. Anatomical relationshipsof urinary bladders compared: their potential role in the developmentof bladder tumours in humans and rats. Food Chem Toxicol. 1995;33:705-714.
66. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1105.
67. Messana I, Forni F, Ferrari F, Rossi C, Giardina B, Zuppi C. Proton nuclear magnetic resonance spectral profilesof urine in type II diabetic patients. Clin Chem. 1998;44:1529-1534. (Pubitemid 28309115)
68. van Doorn M, Vogels J, Tas A, van Hoogdalem EJ, Burggraaf J, Cohen A, van der Greef J. Evaluationof metabolite profiles as biomarkers for the pharmacological effectsof thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol. 2007;63:562-574. (Pubitemid 46632578)
69. Davis SN, Umpierrez GE. Diabetic ketoacidosis in type 2 diabetes mellitus - pathophysiology and clinical presentation. Nat Clin Pract Endocrinol Metab. 2007;3:730-731. (Pubitemid 47622599)
70. Tai TY, Tseng CH, Sung SM, Huang RF, Chen CZ, Tsai SH: Retinopathy, neuropathy and nephropathy in non-insulin-dependent diabetic patients. J Formosan Med Assoc. 1991;90:936-940.
71. Akoudad S, Szklo M, McAdams MA, Fulop T, Anderson CA, Coresh J, Kottgen A. Correlatesof kidney stone disease differ by race in a multi-ethnic middle-aged population: the ARIC study. Prev Med. 2010;51:416-420.
72. Chou YH, Li WM, Li CC, Huang SP, Liu CC, Wu WJ, et al. Clinical studyof uric acid urolithiasis. Kaohsiung J Med Sci. 2007;23:298-301.
73. Jeong IG, Kang T, Bang JK, Park J, Kim W, Hwang SS, et al. Association between metabolic syndrome and the presenceof kidney stones in a screened population. Am J Kidney Dis. 2011;58:383-388.
74. Tseng CH. Differential dyslipidemia associated with albuminuria in type 2 diabetic patients in Taiwan. Clin Biochem. 2009;42:1019-1024.
75. Tseng CH, Tseng CP, Chong CK. Joint effectsof hypertension, smoking, dyslipidemia andobesity and angiotensin-converting enzyme DD genotypeon albuminuria in Taiwanese patients with type 2 diabetes mellitus. Clin Biochem. 2010;43:629-634.
76. Nissen SE. The rise and fallof rosiglitazone. Eur Heart J. 2010;31:773-776.
77. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effectsof pioglitazone in patients with type 2 diabetes withor without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865-873. (Pubitemid 46568445)
78. Erdmann E, Dormandy J,Wilcox R, Massi-Benedetti M, Charbonnel B. PROactive 07: pioglitazone in the treatmentof type 2 diabetes: resultsof the PROactive study. Vasc Health Risk Manag. 2007;3:355-370. (Pubitemid 47542597)
79. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerabilityof pioglitazone in high-risk patients with type 2 diabetes: anoverviewof data from PROactive. Drug Saf. 2009;32:187-202.
80. Hering-Smith KS, Gambala CT, Hamm LL. Citrate and succinate transport in proximal tubule cells. Am J Physiol Renal Physiol. 2000;278:F492-498. (Pubitemid 30163249)
81. Wagner CA, Mohebbi N. Urinary pH and stone formation. J Nephrol. 2010;23(Suppl. 16):S165-169.
82. Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, et al. Fasting blood glucose and cancer risk in a cohortofmore than 140,000 adults in Austria. Diabetologia. 2006;49:945-952.
83. Piatkiewicz P, Czech A. Glucose metabolism disorders and the riskof cancer. Arch Immunol Ther Exp (Warsz). 2011;59:215-230.
84. US Food and Drug Administration, Endocrinologic & Metabolic Advisory Committee. Dapagliflozin (BMS-512148) EMDAC Background Document. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262996.df (accessed August 10, 2011).
85. Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF Jr. Urinary tract infection and riskof bladder cancer. Am J Epidemiol. 1984;119:510-515. (Pubitemid 14134659)
86. La Vecchia C, Negri E, D'Avanzo B, Savoldelli R, Franceschi S. Genital and urinary tract diseases and bladder cancer. Cancer Res. 1991;51:629-631.
87. Colao A, Vitale P, Faggiano A. Diabetes and cancer. Front Endocrin. 2011;2:22.
88. Fang JL, Stingley RL, Beland FA, Harrouk W, Lumpkins DL, Howard P. Occurrence, efficacy, metabolism, and toxicityof triclosan. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010;28:147-171.
89. Chen T. The roleof MicroRNA in chemical carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010;28:89-124.
90. Guo L, Mei N, Xia Q, Chen T, Chan PC, Fu PP. Gene expression profiling as an initial approach for mechanistic studiesof toxicity and tumorigenicityof herbal plants and herbal dietary supplements. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010;28:60-87.
91. Svircev Z, Baltíc V, Gantar M, Jukovíc M, Stojanovíc D, Baltíc M. Molecular aspectsof microcystin-induced hepatotoxicity and hepatocarcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010;28:39-59.
92. Kuo CY, Wang JY, Yeh CJ, Chen MC, Kuo CW, Chiang CY, Chou HL. Metal exposure for residents near diesel transport routes. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010;28:22-38.
93. Fairlie I. Childhood cancer near German nuclear power stations. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010;28:1-21.
94. Tseng CH, Chong CK, Tai TY. Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Dabetologia. 2009;52:240-246.
95. Tseng CH. Prostate cancer mortality in Taiwanese men: increasing agestandardized trend in general population and increased risk in diabetic men. Ann Med. 2011;43:142-150.
96. Tseng CH. Diabetes and riskof prostate cancer: a study using the National Health Insurance. Diabetes Care. 2011;34:616-621.
97. Tseng CH. Diabetes conveys a higher riskof gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan. Gut. 2011;60:774-779.
98. Tseng CH. Diabetes and non-Hodgkin's lymphoma: analysesof prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan. Ann Oncol. 2012;23:153-158.
99. Tseng CH. Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study. BMC Gastroenterology 2012;12:46.